Effects of ertugliflozin on uric acid and gout-related outcomes: post hoc analyses from VERTIS CV

被引：0
|
作者：
Sridhar, V. S. [1 ,2 ]
Cosentino, F. [3 ,4 ]
Dagogo-Jack, S. [5 ]
Pratley, R. [6 ]
Frederich, R. [7 ]
Essex, M. Noyes [8 ]
Maldonado, M. [9 ]
Liu, C. -C. [10 ]
Mancuso, J. P. [11 ]
Cherney, D. Z. I. [1 ,2 ]
机构：
[1] Univ Hlth Network, Div Nephrol, Dept Med, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Karolinska Inst, Unit Cardiol, Stockholm, Sweden
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[6] AdventHlth Translat Res Inst, Orlando, FL USA
[7] Pfizer Inc, Collegeville, PA USA
[8] Pfizer Inc, New York, NY USA
[9] MSD Ltd, London, England
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Pfizer Inc, Groton, CT 06340 USA
来源：
DIABETOLOGIA | 2022年 / 65卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
621
引用
收藏
页码：S318 / S319
页数：2
相关论文
共 50 条
  • [21] Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV
    Dagogo-Jack, Samuel
    Cannon, Christopher P.
    Cherney, David Z., I
    Cosentino, Francesco
    Liu, Jie
    Pong, Annpey
    Gantz, Ira
    Frederich, Robert
    Mancuso, James P.
    Pratley, Richard E.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1245 - 1254
  • [22] Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
    Dagogo-Jack, Samuel
    Frederich, Robert
    Liu, Jie
    Cannon, Christopher P.
    Shi, Harry
    Cherney, David Z., I
    Cosentino, Francesco
    Masiukiewicz, Urszula
    Gantz, Ira
    Pratley, Richard E.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (08): : 2042 - 2051
  • [23] Hepatic Steatosis Index and Fibrosis-4 Scores in Patients With Type 2 Diabetes - Post Hoc Analyses from VERTIS CV
    Corbin, Karen D.
    Dagogo-Jack, Samuel
    Cannon, Christopher P.
    Cherney, David Z.
    Cosentino, Francesco
    McGuire, Darren K.
    Shih, Weichung J.
    Frederich, Robert
    Liu, Jie
    Lin, Jianxin
    Cater, Nilo B.
    Pratley, Richard E.
    [J]. CIRCULATION, 2021, 144
  • [24] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    Cherney, David Z. I.
    Charbonnel, Bernard
    Cosentino, Francesco
    Dagogo-Jack, Samuel
    McGuire, Darren K.
    Pratley, Richard
    Shih, Weichung J.
    Frederich, Robert
    Maldonado, Mario
    Pong, Annpey
    Cannon, Christopher P.
    [J]. DIABETOLOGIA, 2021, 64 (06) : 1256 - 1267
  • [25] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
    David Z. I. Cherney
    Bernard Charbonnel
    Francesco Cosentino
    Samuel Dagogo-Jack
    Darren K. McGuire
    Richard Pratley
    Weichung J. Shih
    Robert Frederich
    Mario Maldonado
    Annpey Pong
    Christopher P. Cannon
    [J]. Diabetologia, 2021, 64 : 1256 - 1267
  • [26] Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial
    Pratley, Richard E.
    Cannon, Christopher P.
    Cherney, David Z., I
    Cosentino, Francesco
    McGuire, Darren K.
    Essex, Margaret Noyes
    Lawrence, David
    Jones, Philip L. S.
    Liu, Jie
    Adamsons, Ingrid
    Dagogo-Jack, Samuel
    [J]. LANCET HEALTHY LONGEVITY, 2023, 4 (04): : E143 - E154
  • [27] Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter?
    Wu, Eric Q.
    Patel, Pankaj A.
    Mody, Reema R.
    Yu, Andrew P.
    Cahill, Kevin E.
    Tang, Jackson
    Krishnan, Eswar
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (05) : 1032 - 1040
  • [28] Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
    Cherney, D. Z. I.
    Segar, M.
    Pandey, A.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C. -C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2925 - 2925
  • [29] DECISION SUPPORT, ALLOPURINOL USE, AND URIC ACID TESTING IN PATIENTS WITH GOUT-RELATED VISITS AT ONE VA MEDICAL CENTER
    Boggan, Joel C.
    Schulteis, Ryan D.
    Simel, David L.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2016, 31 : S173 - S173
  • [30] Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial
    Segar, M. W.
    Pandey, A.
    Cherney, D. Z. I.
    Cannon, C. P.
    Cosentino, F.
    Dagogo-Jack, S.
    Pratley, R. E.
    Shih, W. J.
    Frederich, R.
    Cater, N. B.
    Maldonado, M.
    Liu, J.
    Liu, C.
    Pong, A.
    McGuire, D. K.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2649 - 2649
12345